Table 3 Six-month risk of cardiorenal composite outcome by change in each RAASi class following an HK episode
From: Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
RAASi class | US | Japan | ||||
|---|---|---|---|---|---|---|
N | 6-month risk, % (95% CI) | p-valuea | N | 6-month risk, % (95% CI) | p-valuea | |
ACEi | ||||||
Maintained or up-titrated | 3564 | 9.6 (8.6–10.6) | 745 | 19.4 (16.5–22.2) | ||
Down-titrated (> 25%) | 373 | 17.1 (13.0–21.0) | 44 | 29.5 (14.7–41.8) | ||
Discontinued | 1708 | 16.3 (14.5–18.1) | < 0.001 | 263 | 21.8 (16.6–26.6) | 0.37 |
ARB | ||||||
Maintained or up-titrated | 1954 | 10.2 (8.8–11.5) | 2350 | 14.1 (12.7–15.6) | ||
Down-titrated (> 25%) | 163 | 20.5 (13.7–26.7) | 159 | 19.0 (12.6–24.9) | ||
Discontinued | 896 | 20.6 (17.9–23.2) | < 0.001 | 842 | 19.9 (17.2–22.6) | < 0.001 |
ARNi | ||||||
Maintained or up-titrated | 337 | 20.2 (15.7–24.5) | 26 | < 11 pts | ||
Down-titrated (> 25%) | 22 | < 11 pts | < 11 pts | < 11 pts | ||
Discontinued | 128 | 34.4 (25.4–42.2) | < 0.001 | < 11 pts | < 11 pts | N/A |
MRA | ||||||
Maintained or up-titrated | 1271 | 18.1 (15.8–20.2) | 744 | 17.7 (14.9–20.4) | ||
Down-titrated (> 25%) | 100 | 17.9 (9.7–25.2) | 106 | 16.3 (8.9–23.2) | ||
Discontinued | 908 | 20.9 (18.1–23.5) | 0.14 | 808 | 22.1 (19.2–25.0) | 0.02 |